Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy
- Novo Nordisk is cutting the price of Wegovy to $499 per month, which is a 60% discount from the list price of $1,349.02.
- The new pricing applies to uninsured patients or those with commercial insurance that does not cover obesity treatments, effective immediately.
- Eli Lilly reduced the price of Zepbound to $399 for its lowest dose, through a similar program.
- The U.S. Food and Drug Administration has removed semaglutide, the active ingredient in both drugs, from its drug shortage list, allowing for more supply availability.
Insights by Ground AI
Does this summary seem wrong?
24 Articles
24 Articles
All
Left
7
Center
8
Right
3
Coverage Details
Total News Sources24
Leaning Left7Leaning Right3Center8Last UpdatedBias Distribution44% Center
Bias Distribution
- 44% of the sources are Center
44% Center
L 39%
C 44%
R 17%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage